Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Edgewise Therapeutics Inc EWTX

Healthcare
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. It has built its muscle-focused drug discovery platform. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small... see more

Recent & Breaking News (NDAQ:EWTX)

Edgewise Therapeutics to Present at Upcoming Investor Conferences

Business Wire November 9, 2022

Edgewise Therapeutics Reports Third Quarter 2022 Financial Results

Business Wire November 3, 2022

Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)

Business Wire October 27, 2022

Edgewise Therapeutics Announces Positive 6-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

Business Wire October 13, 2022

Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 27th International Hybrid Annual Congress of the World Muscle Society

Business Wire October 6, 2022

Edgewise Therapeutics Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Business Wire September 16, 2022

Edgewise Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

Business Wire September 13, 2022

Edgewise Therapeutics Announces Proposed Offering of Common Stock

Business Wire September 13, 2022

Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

Business Wire September 11, 2022

Edgewise Therapeutics Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)

Business Wire September 7, 2022

Edgewise Therapeutics Reports Second Quarter 2022 Financial Results

Business Wire August 4, 2022

Edgewise Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on August 9

Business Wire August 3, 2022

Edgewise Therapeutics Now Enrolling CANYON Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD)

Business Wire July 12, 2022

Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

Business Wire June 20, 2022

New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) to be Presented at the Upcoming New Directions in Biology and Disease of Skeletal Muscle Conference

Business Wire June 16, 2022

Edgewise Therapeutics to Present at Upcoming Investor Conferences

Business Wire May 31, 2022

Edgewise Therapeutics Reports First Quarter 2022 Financial Results

Business Wire May 11, 2022

Edgewise Therapeutics to Present at Upcoming Investor Conferences

Business Wire May 3, 2022

Edgewise-Funded Natural History Trial of Becker Muscular Dystrophy (BMD) Now Enrolling

Business Wire April 14, 2022

Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2022 Annual MDA Clinical and Scientific Conference

Business Wire March 8, 2022